Page 17 - Read Online
P. 17

Onea et al. Vessel Plus 2023;7:13  https://dx.doi.org/10.20517/2574-1209.2023.11  Page 11 of 12

               Financial support and sponsorship
               None.


               Conflicts of interest
               Bernardo Cortese is a consultant for several DCB producers: B. Braun, Medtronic, Concept Medical, and
               MedAlliance.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2023.

               REFERENCES
               1.       Morice M, Serruys P, Sousa E. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary
                   revascularization. ACC Current Journal Review 2002;11:61.  DOI
               2.       Neumann FJ, Sousa-Uva M. ‘Ten commandments’ for the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J
                   2019;40:79-80.  DOI  PubMed
               3.       Costopoulos C, Latib A, Naganuma T, et al. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the
                   treatment of de novo diffuse coronary disease. JACC Cardiovasc Interv 2013;6:1153-9.  DOI  PubMed
               4.       van Beek KAJ, van Steenbergen GJ, Vervaat FE, et al. Single center experience in the treatment of hemodynamically significant
                   diffuse coronary artery disease of the left anterior descending. Int J Cardiol 2022;352:40-4.  DOI  PubMed
               5.       Cortese B, Sanchez-Jimenez E. Back to the future: DCB use instead of DES for the treatment of complex, native coronary artery
                   disease. Eur Heart J Suppl 2021;23:E63-7.  DOI  PubMed  PMC
               6.       Youn YJ, Jeon HS, Kim YI, et al. Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients
                   with diffuse long coronary artery disease. Clin Cardiol 2023;46:416-24.  DOI  PubMed  PMC
               7.       Brugaletta S, Gomez-Lara J, Ortega-Paz L, et al. 10-year follow-up of patients with everolimus-eluting versus bare-metal stents after
                   ST-segment elevation myocardial infarction. J Am Coll Cardiol 2021;77:1165-78.  DOI  PubMed
               8.       Kufner S, Ernst M, Cassese S, et al; ISAR-TEST-5 Investigators. 10-year outcomes from a randomized trial of polymer-free versus
                   durable polymer drug-eluting coronary stents. J Am Coll Cardiol 2020;76:146-58.  DOI  PubMed
               9.       Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to
                   guide treatment and state-of-the-art review. Circ Cardiovasc Interv 2019;12:e007023.  DOI  PubMed
               10.      Chen Z, Matsumura M, Mintz GS, et al. Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment
                   of second-generation drug-eluting stent restenosis. Circ Cardiovasc Interv 2022;15:e011693.  DOI  PubMed
               11.      Konigstein M, Madhavan MV, Ben-Yehuda O, et al. Incidence and predictors of target lesion failure in patients undergoing
                   contemporary DES implantation-individual patient data pooled analysis from 6 randomized controlled trials.  Am Heart J
                   2019;213:105-11.  DOI  PubMed  PMC
               12.      Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance
                   angiography. Heart 2014;100:153-9.  DOI  PubMed
               13.      Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23.
                   DOI  PubMed  PMC
               14.      Généreux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting
                   stents: insights from the xience V coronary stent system trials. Circ Cardiovasc Interv 2015;8:e001362.  DOI  PubMed
               15.      Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence
                   tomography. Circulation 2016;133:650-60.  DOI  PubMed
               16.      Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini GG, Polimeni A. Stent thrombosis and restenosis with contemporary
                   drug-eluting stents: predictors and current evidence. J Clin Med 2023;12:1238.  DOI  PubMed  PMC
               17.      Lee CW, Ahn JM, Lee JY, et al; OPERA Steering Committee and Investigators. Long-term (8 year) outcomes and predictors of major
                   adverse cardiac events after full metal jacket drug-eluting stent implantation. Catheter Cardiovasc Interv 2014;84:361-5.  DOI
                   PubMed
               18.      Kjøller-Hansen L, Kelbæk H, Christiansen EH, et al. Predictors of 10-year stent-related adverse outcomes after coronary drug-eluting
                   stent implantation: the importance of stent size. Cardiology 2021;146:705-12.  DOI
   12   13   14   15   16   17   18   19   20   21   22